Investment Thesis
Clover Health demonstrates strong top-line growth (+40.3% YoY) and maintains a fortress balance sheet with zero debt and $173.3M cash, supported by healthy free cash flow of $107M. However, the dramatic 98.9% collapse in net income coupled with razor-thin operating margins of 3.6% and weak capital returns (ROE 8.1%, ROA 3.9%) signal severe operational challenges that contradict growth momentum and warrant caution.
Strengths
- Strong revenue growth of 40.3% YoY demonstrating market traction
- Zero long-term debt with $173.3M cash position providing financial flexibility
- Robust free cash flow generation of $107M (14.3% FCF margin) despite low profitability
- Low capital requirements ($854K capex) reducing reinvestment burden
Risks
- Net income collapsed 98.9% YoY despite strong revenue growth, indicating severe operational deterioration
- Net margin of only 3.6% is critically thin for a healthcare services business with 36.2% gross margins
- Weak return on equity (8.1%) and return on assets (3.9%) reflect poor capital deployment efficiency
- Operating expense structure appears unsustainable relative to revenue base
Key Metrics to Watch
- Quarterly net income trend and operating margin expansion path
- Operating expense ratio to revenue and cost structure breakdown
- Medical loss ratio and claims performance by segment
- Year-over-year profitability recovery indicators and management guidance
Financial Metrics
Revenue
749.2M
Net Income
27.3M
EPS (Diluted)
$0.05
Free Cash Flow
107.0M
Total Assets
697.7M
Cash
173.3M
Profitability Ratios
Gross Margin
36.2%
Operating Margin
3.6%
Net Margin
3.6%
ROE
8.1%
ROA
3.9%
FCF Margin
14.3%
Balance Sheet & Liquidity
Current Ratio
1.33x
Quick Ratio
1.33x
Debt/Equity
0.00x
Debt/Assets
51.4%
Interest Coverage
3,904.86x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T08:45:48.598197 |
Data as of: 2026-03-31 |
Powered by Claude AI